Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

C4 Therapeutics Inc (CCCC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow C4's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.90 +0.04    +0.58%
23/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
6.98
+0.08
+1.16%
4:33:42 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 888,997
  • Bid/Ask: 6.98 / 7.26
  • Day's Range: 6.89 - 7.15
C4 6.90 +0.04 +0.58%

C4 Therapeutics Inc Company Profile

 
Get an in-depth profile of C4 Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

145

Equity Type

ORD

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Contact Information

Address 490 Arsenal Way Suite120
Watertown, 02472
United States
Phone 617 231 0700
Fax -

Top Executives

Name Age Since Title
Andrew J. Hirsch 51 2020 CEO, President & Director
Kenneth C. Anderson 71 2015 Co-Founder, Independent Director & Member of Scientific Advisory Board
Donna Roy Grogan 66 2022 Independent Director
Laura Bessen - 2022 Independent Director
Bruce L. Downey 76 2015 Chairman & Lead Independent Director
Nathanael S. Gray - 2016 Co-Founder & Member of Scientific Advisory Board
Christopher J. Kirk 50 2016 Member of Scientific Advisory Board
Glenn Russell Dubin 66 2021 Independent Director
Ross L. Levine 51 2017 Member of Scientific Advisory Board
Randi Isaacs 67 - Member of Clinical Advisory Board
Scott A. Armstrong - 2017 Member of Scientific Advisory Board
Christopher J. Bowden 62 - Member of Clinical Advisory Board
Hagop Youssoufian 66 2023 Member of Clinical Advisory Board
Malcolm S. Salter 83 2015 Independent Director
Utpal Koppikar 52 2022 Independent Director
Beni B. Wolf - - Member of Clinical Advisory Board
Ryan B. Corcoran - 2019 Member of Scientific Advisory Board
Owen P. Hughes 48 2023 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CCCC Comments

Write your thoughts about C4 Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Kevin Rush
Kevin Rush Dec 29, 2023 9:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy and hold
Dec 22, 2023 4:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.pharmaceutical-technology.com/data-insights/c4-therapeutics-gets-grant-for-cereblon-binders-for-degradation-of-ikaros-or-aiolos/?utm_source=lgp6-patents-grant&utm_medium=24-257160&utm_campaign=recommended-articles&cf-view&cf-minimized&cf-view&cf-closed
Pet Er
Pet Er Dec 14, 2023 9:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Do you think those will go above $6 in 1 day ?
Dec 13, 2023 11:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🚀
Kevin Rush
Kevin Rush Dec 13, 2023 10:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1000 shaes. in
Dec 12, 2023 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buena colaboracion! 🚀🚀
pablo trader
pablo trader Apr 08, 2022 1:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
for the toilet
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email